The Effects of a Mediterranean Diet in Pediatric Hyperlipidemia (EARLYMedit)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Children with high cholesterol levels are especially vulnerable and are at high risk for early onset coronary heart disease (CHD). Endothelial dysfunction, the earliest phase of CHD, is present in children with elevated cholesterol levels as early as 8 years of age. The long term objective of this study is to develop dietary interventions for the prevention and treatment of endothelial dysfunction in children with common lipid disorders including familial hypercholesterolemia (FH) and familial combined hyperlipidemia (FCH). Increasing evidence suggests that the Mediterranean diet and ω-3 fatty acids found in fish have cardioprotective effects. The specific aims of the study are to: determine whether a Mediterranean diet alone or combined with ω-3 fatty acid (eicosapentaenoic acid)improves endothelial function; evaluate the effects of the dietary interventions on lipids and lipoprotein subclasses; evaluate the effects of the dietary interventions on biomarkers for oxidative stress and inflammation. This study is a randomized, double-blind, placebo-controlled clinical trial that includes 34 children (ages 8-17) treated with the Mediterranean diet and ω-3 fatty acid supplements. A dietary educational behavioral intervention will be conducted over 6 months with individual counseling and group sessions. Endothelial function will be measured noninvasively by high resolution ultrasound of the brachial artery at baseline, 6, 12, 18 and 24 weeks. This study is unique because it is a new intervention designed for children at high risk for early CHD with a dietary component and supplementation with ω-3 fatty acids. If effective, this intervention would be broadly applicable in the community and lend valuable insight about dietary therapy to prevent the progression of CHD in hyperlipidemic children.
| Condition | Intervention | Phase |
|---|---|---|
|
Hyperlipidemia |
Dietary Supplement: Omega-3 fatty acid (Eicosapentaenoic acid) |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Prevention |
| Official Title: | Endothelial Assessment of Risk From Lipids in Youth: Mediterranean Diet |
- Endothelial function [ Time Frame: Measured every 6 wks for 6 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 34 |
| Study Start Date: | January 2010 |
| Estimated Study Completion Date: | August 2013 |
| Estimated Primary Completion Date: | January 2013 (Final data collection date for primary outcome measure) |
-
Dietary Supplement: Omega-3 fatty acid (Eicosapentaenoic acid)
Eligibility| Ages Eligible for Study: | 8 Years to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Children (8-17 years old)
- Familial Hypercholesterolemia or Familial Combined Hyperlipidemia
- Able to read, write and understand English
- Parental consent and child assent
- Access to a computer and internet and literacy in the use of the internet
- The attendance of a parent to each educational session.
Exclusion Criteria:
- Chronic systemic illness with or without secondary hyperlipidemia
- Current smoking
Contacts and Locations| Contact: Marguerite M. Engler, PhD | 301-451-6175 | marguerite.engler@nih.gov |
| United States, California | |
| University of California, San Francisco | Recruiting |
| San Francisco, California, United States, 94143 | |
| Contact: Dr. Marguerite M. Engler, PhD, MS 415-476-0983 marguerite.engler@nursing.ucsf.edu | |
| Contact: Dr. Mary B. Engler, PhD, MS 415-476-0984 mary.engler@nursing.ucsf.edu | |
| Principal Investigator: Marguerite M. Engler, PhD, MS | |
| Principal Investigator: | Marguerite M. Engler, PhD | University of California, San Francisco |
| Principal Investigator: | Mary B. Engler, PhD | University of California, San Francisco |
More Information
No publications provided
| Responsible Party: | University of California, San Francisco |
| ClinicalTrials.gov Identifier: | NCT01308710 History of Changes |
| Other Study ID Numbers: | R56NR004909 |
| Study First Received: | March 3, 2011 |
| Last Updated: | April 18, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of California, San Francisco:
|
endothelial function lipids pediatrics |
Additional relevant MeSH terms:
|
Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases |
ClinicalTrials.gov processed this record on June 18, 2013